Stockreport

Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics [Yahoo! Finance]

Merck & Company, Inc. (new)  (MRK) 
Last merck & company, inc. (new) earnings: 4/28 06:45 am Check Earnings Report
US:NYSE Investor Relations: investors.merck.com/home/default.aspx
PDF Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales milestones INNSBRUCK, Austria, April 15, 2025 (GLOBE NEWSWIRE) - [Read more]